116: Can Weight Loss Medications (GLP1s) Reduce Breast Cancer Risk?

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

116: Can Weight Loss Medications (GLP1s) Reduce Breast Cancer Risk?

Ascolta gratuitamente

Vedi i dettagli del titolo

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Ancora nessuna recensione